3 Numbers To Consider Before Buying GlaxoSmithKline plc

Here are three numbers to assess when evaluating GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are always plenty of numbers to evaluate when weighing up whether to buy a particular share.

Today I’m going to quickly review three figures for anyone thinking about investing in GlaxoSmithKline (LSE:GSK) (NYSE: GSK.US).

1. 13

According to chief executive Sir Andrew Witty’s second-quarter update, 13 is the number of new treatments GlaxoSmithKline is expecting to deliver Phase III trial data on during 2013/14.  

Like most pharmaceutical companies, GlaxoSmithKline has not been immune to the challenge of patent expiries eroding its profit margins over the past several years

It’s therefore vital that GlaxoSmithKline keeps continuously developing its pipeline of new treatments and ensures enough of them make it through the testing and approval stages to become fully fledged commercial products.

I’ll be watching closely to see how many of the 13 candidates make it through the Phase III stage, ready to be submitted for regulatory approval.

Not all of them will, but the higher the number, the greater my confidence in GlaxoSmithKline’s ability to keep on generating profits in the medium to long term.

2. 116.6p

That’s management’s year-end prediction for earning per share, according to its Q2 statement in July, when is said it expected core EPS growth in 2013 to be in the range of 3-4%.

With the shares currently trading at around 1,662p, that projection puts GlaxoSmithKline on a trailing P/E of 14.7 and a forecast P/E of 14.3, which is just below the FTSE 100 average of 14.8.  

But while the EPS growth is welcome, if achieved, it will only bring earnings back to a level seen in 2011.

3. 1,428p per share

That’s the average price paid by GlaxoSmithKline for the 174.5 million shares it bought back in 2012 — some £2.5bn worth.

In its Q1 statement, GlaxoSmithKline stated its intention to buy back a further £1-2bn worth of shares in 2013/14.

With the recent price at 1,661p, GlaxoSmithKline is sitting on a 16% gain on last year’s buybacks — the kind of return to shareholders that I like to see!

And just imagine how much further the share price could run up if GlaxoSmithKline delivers on its guidance to deploy a further £2bn on buybacks before the end of the year.

What next?

So there you go, three numbers that may or may not have some bearing on whether you buy shares in GlaxoSmithKline.

If you already own GlaxoSmithKline shares, or are unsure about the pharmaceutical giant’s prospects, you may wish to enjoy this exclusive wealth report, which reviews five other blue chips you can buy today.

Indeed, all five selections offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for this special report now — it’s free for a limited time only.

> Andrew owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »